Hatchtech Pty Ltd   Report issue

For profit Phase 1 Phase 3
Founded: Melbourne Australia (2001)
Status: Left NME R&D (2015)

Organization Overview

First Clinical Trial
2011
NCT01336647
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

abametapir (9 trials)

Drugs in Phase 1 Trials (3)

moxifloxacin (avelox) (1 trial)

sodium chloride (2 trials)

sodium monododecyl sulfate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lice Infestations (Phase 3)

Mite Infestations (Phase 3)

Parasitic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 4